Abbott Laboratories (ABT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Abbott Laboratories reported revenue of $44.33B, up 5.7% from $41.95B the year before. Net income was $6.52B (a 14.7% net margin), or $3.72 per diluted share. Gross margin was 56.4% and operating margin was 18.2%. Operating activities generated $9.57B of cash, leaving $7.39B of free cash flow. At fiscal year end, Abbott Laboratories held $86.71B in total assets against $34.58B in total liabilities, including $8.52B of cash and equivalents.
Open the full interactive Abbott Laboratories financials → Quarterly statements, key ratios, valuation history and price charts.
Abbott Laboratories Key Stats
| Share Price | $102.61 |
|---|---|
| Market Cap | $178.85B |
| P/E Ratio | 27.6 |
| Revenue YoY Growth | +5.7% |
| 52-Week Range | $81.98 – $130.26 |
| Shares Outstanding | 1.74 billion (basic, 2026 Q2) |
Abbott Laboratories Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $34.61B | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B |
| Cost of Goods Sold | $15.00B | $18.54B | $19.14B | $17.98B | $18.71B | $19.32B |
| Gross Profit | $19.61B | $24.54B | $24.51B | $22.13B | $23.24B | $25.01B |
| Operating Income | $5.36B | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B |
| Pre-Tax Income | $4.97B | $8.21B | $8.31B | $6.66B | $7.01B | $8.47B |
| Income Tax | $497.0M | $1.14B | $1.37B | $941.0M | -$6.39B | $1.94B |
| Net Income | $4.50B | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B |
| Diluted EPS | $2.50 | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
Abbott Laboratories Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $11.37B | $11.46B | $11.16B | $12.59B |
| Net Income | $1.64B | $1.78B | $1.08B | $928.0M |
| Diluted EPS | $0.94 | $1.02 | $0.61 | $0.53 |
Abbott Laboratories Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.84B | $9.80B | $9.88B | $6.90B | $7.62B | $8.52B |
| Current Assets | $20.44B | $24.24B | $25.22B | $22.67B | $23.66B | $26.00B |
| Total Assets | $72.55B | $75.20B | $74.44B | $73.21B | $81.41B | $86.71B |
| Current Liabilities | $11.91B | $13.11B | $15.49B | $13.84B | $14.16B | $16.50B |
| Total Long-Term Debt | $18.53B | $18.05B | $16.77B | $14.68B | $14.12B | $12.93B |
| Total Liabilities | $39.76B | $39.39B | $37.75B | $34.61B | $33.75B | $34.58B |
| Shareholders' Equity | $32.78B | $35.80B | $36.69B | $38.60B | $47.66B | $52.13B |
Abbott Laboratories Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $7.90B | $10.53B | $9.58B | $7.26B | $8.56B | $9.57B |
| Cash From Investing | -$2.21B | -$2.01B | -$1.74B | -$3.13B | -$2.34B | -$2.42B |
| Cash From Financing | -$2.78B | -$5.49B | -$7.64B | -$7.09B | -$5.40B | -$6.31B |
| Free Cash Flow | $5.72B | $8.65B | $7.80B | $5.06B | $6.35B | $7.39B |
Figures from Abbott Laboratories' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Abbott Laboratories financials page for every line item.
Abbott Laboratories Company Profile
| Ticker | ABT |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Abbott Park, Illinois |
| Incorporated in | Illinois |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000001800 |
Frequently Asked Questions
What was Abbott Laboratories' revenue in fiscal 2025?
Abbott Laboratories (ABT) reported revenue of $44.33B for fiscal 2025.
What is Abbott Laboratories' annual revenue history?
Abbott Laboratories' annual revenue by fiscal year: 2020: $34.61B; 2021: $43.08B; 2022: $43.65B; 2023: $40.11B; 2024: $41.95B; 2025: $44.33B.
What was Abbott Laboratories' net income in fiscal 2025?
Abbott Laboratories reported net income of $6.52B for fiscal 2025.
What was Abbott Laboratories' earnings per share (EPS) in fiscal 2025?
Abbott Laboratories' diluted EPS was $3.72 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Abbott Laboratories generate in fiscal 2025?
Abbott Laboratories generated $7.39B of free cash flow in fiscal 2025.
What was Abbott Laboratories' revenue last quarter?
In its most recent reported quarter (2026 Q2), Abbott Laboratories reported revenue of $12.59B.
How much debt does Abbott Laboratories have?
Abbott Laboratories reported $12.93B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Abbott Laboratories are outstanding?
Abbott Laboratories reported a weighted average of 1.74 billion basic shares outstanding in 2026 Q2.
What is Abbott Laboratories' market cap?
Based on its latest closing price, Abbott Laboratories (ABT) has a market capitalization of about $178.85B.
When does Abbott Laboratories' fiscal year end?
Abbott Laboratories' fiscal year end, as registered with the SEC, is December 31.
Where is Abbott Laboratories headquartered?
Abbott Laboratories lists its business address in Abbott Park, Illinois in its SEC filings.